Expanding the range of bioconjugate vaccines to fight more bacterial threats Omniose is an early-stage biotechnology company developing polysaccharide conjugate vaccines against serious bacterial threats using its proprietary bioconjugation platform. We are expanding the range of bacterial targets that can be addressed with bioconjugate vaccines. Bioconjugation relies on single cells that simultaneously produce a polysaccharide
Location: United States, Missouri, Saint Louis
Employees: 1-10
Total raised: $3.6M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 11.10.2022 | Grant | $3.6M | - |
Mentions in press and media 1
| Date | Title | Description |
| 11.10.2022 | Omniose Receives $3.6M Grant from NIH | Omniose, a Saint Louis, MO-based company developing polysaccharide conjugate vaccines against serious bacterial threats, received a $3.6M grant. The award came from the National Institute of Allergy and Infectious Diseases of the U.S. Natio... |